Q-omics provides the consensus-scored BOD1P2 profile across patient tissues and cancer cell-line models. BOD1P2 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UCS. Additionally, BOD1P2 RNA expression shows 5,280 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCS, and STAD as cancer lineages where BOD1P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.